Novartis, Pear Therapeutics sign development deal for two digital therapeutics

Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia. It ’s the first time a pharma company has made a development deal with a digital therapeutic, according to Pear.
Source: mobihealthnews - Category: Information Technology Source Type: news